Literature DB >> 3817052

New monoclonal antibody enzymoassay for the specific measurement of placental ferritin isotype in hematologic malignancies.

C Moroz, H Bessler, Y Lurie, M Shaklai.   

Abstract

A new enzymoimmunoassay, specific for the measurement of placental ferritin (PLF) isotype, has been described. Two monoclonal antibodies (McAbs) with different binding specificities to placental ferritin have been used in this assay. One antibody (CM-G-8) binds to all ferritins, whereas the second (CM-H-9) binds to placental ferritin only. In addition, a second enzymoassay was developed for the measurement of total common serum ferritin using CM-G-8 McAb. Serum levels of total ferritin and PLF were measured in healthy individuals and in patients with lymphoproliferative diseases and multiple myeloma. The majority of normal subjects were deficient in PLF in the serum. Increased serum levels of PLF were observed in patients with Hodgkin's lymphoma and non-Hodgkin's lymphoma of low and intermediate grades, as well as in patients with acute lymphocytic leukemia (ALL). Total ferritin was also elevated in these patients. Chronic lymphocytic leukemia (CLL) and multiple myeloma patients exhibited normal levels of common serum ferritin, whereas PLF in the serum was lacking.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3817052

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  11 in total

1.  Placental isoferritin associated p43 antigen correlates with features of high differentiation in breast cancer.

Authors:  H R Rosen; C Moroz; A Reiner; M Reinerova; M Stierer; J Svec; M Schemper; R Jakesz
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

2.  T-cell mitogenesis stimulates the synthesis of a mRNA species coding for a 43-kDa peptide reactive with CM-H-9, a monoclonal antibody specific for placental isoferritin.

Authors:  C Moroz; N Shterman; B Kupfer; I Ginzburg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

3.  Placental isoferritin as a physiological downregulator of cellular immunoreactivity during pregnancy.

Authors:  L Sirota; B Kupfer; C Moroz
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

4.  Growth stimulation of ferritin of human leukemia cells in vitro.

Authors:  N Kikyo; K Hagiwara; Y Yazaki; T Okabe
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

5.  Elevated serum placental isoferritin in newly diagnosed type 1 (insulin-dependent) diabetes mellitus. A possible marker for identification of high risk subjects.

Authors:  S Assa; C Moroz
Journal:  Diabetologia       Date:  1990-09       Impact factor: 10.122

6.  The immunosuppressive human placental ferritin subunit p43 is produced by activated CD4+ lymphocytes.

Authors:  B Garty; E Kaminsky; C Moroz
Journal:  Clin Diagn Lab Immunol       Date:  1995-03

7.  Placental isoferritin (PLF) in comparison with MCA and CEA in advanced breast cancer--first data from a pilot study.

Authors:  M Stierer; H R Rosen; E Forster; C Moroz
Journal:  Breast Cancer Res Treat       Date:  1991-11       Impact factor: 4.872

8.  Difference in the placental ferritin levels measured by a specific monoclonal antibody enzymoassay in preterm and term delivery.

Authors:  C Moroz; H Bessler; L Sirota; F Dulitzky; M Djaldetti
Journal:  Clin Exp Immunol       Date:  1987-09       Impact factor: 4.330

9.  Placental ferritin in coeliac disease: relation to clinical stage, origin, and possible role in the pathogenesis of malignancy.

Authors:  G Dinari; I Zahavi; H Marcus; C Moroz
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

10.  Antibodies to placental immunoregulatory ferritin with transfer of polyclonal lymphocytes arrest MCF-7 human breast cancer growth in a nude mouse model.

Authors:  Marisa Halpern; Muayad A Zahalka; Leonid Traub; Chaya Moroz
Journal:  Neoplasia       Date:  2007-06       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.